Neovacs acquires Interferon Alpha manufacturing technology from AMEGABIOTECH

16-Nov-2016 - Neovacs, a manufacturer of active immunotherapies for the treatment of autoimmune diseases, announced an agreement with the Argentinean company AMEGABIOTECH to acquire its Interferon Alpha (IFNα) manufacturing license. IFNα is a key component of Neovacs' lead therapeutic candidate, IFNα Kinoid, ...

Neovacs raises 7.5 million Euro

29-Jun-2015 - Neovacs announced that it has received commitments from three U.S. institutional investors for a capital increase totaling 7,500,000 euros.Participation in the capital increase is limited to biotechnology-focused institutional investors. Neovacs will issue a total of 7,500,000 securities at a ...

Neovacs froms U.S. subsidiary

24-Mar-2015 - Neovacs announced the establishment of its wholly-owned U.S. subsidiary, Neovacs, Inc. Neovacs, Inc. is headquartered in Boston and has been incorporated in Delaware. The creation of this U.S. subsidiary marks an important strategic step for Neovacs, as the Company extends its clinical ...

Neovacs strengthens scientific leadership through executive appointments

12-Mar-2015 - Neovacs announced the enhancement of its scientific leadership team with the appointment of Therese Croughs, M.D., as Chief Medical Officer, effective immediately. Dr. Croughs replaces Pierre Vandepapeliere who is leaving the Company to pursue other opportunities. Additionally, Géraldine ...

NEOVACS announces top-line phase IIb clinical trial results of TNF-Kinoid in Rheumatoid Arthritis

19-Dec-2014 - NEOVACS announced top line data on the Phase IIb clinical trial of TNF-Kinoid in Rheumatoid Arthritis (RA). This trial confirmed the immunogenicity and good tolerance of TNF-Kinoid with no safety issues, but did not meet its primary efficacy endpoint."We are disappointed that our TNF-Kinoid Phase ...

Phase I/II clinical study of Neovac's IFNα-Kinoid for lupus fully enrolled

Initial results expected in April 2011

22-Feb-2011 - Neovacs announced that its IFN-K-001 clinical study has recruited all 28 patients called for by the study protocol and consistent with the Company’s development plan. Initial results will be the subject of a poster presentation at the 8th European Lupus Meeting on April 8th in Porto. The ...

Neovacs initiates a Phase II clinical study of its TNF‐Kinoid in Crohn’s Disease Patients

12-Jan-2011 - Neovacs announced the start of a Phase 2 international clinical trial to study the efficacy of the TNF‐Kinoid in patients suffering from Crohn’s Disease. Consistent with the indications in the Company’s announcement of 8th December 2010, at the end of December, Neovacs received consents from the ...

Encouraging results from the Phase I/II clinical trial of TNF-Kinoid in Crohn's Disease

09-Dec-2010 - Neovacs announced the final results of its Phase I/II clinical trial of TNF-Kinoid which showed the drug candidate's excellent safety profile in all subjects, an immune response to the drug as intended, and a high clinical response rate, with clinical remission (absence of symptoms) in almost ...

Neovacs appoints Florence Hocdée-Leroy as Director of Communications and Investor Relations

Michel Finance steps down as CFO, to be proposed to the Board of Directors at the AGM

19-Oct-2010 - Neovacs announced the appointment of Florence Hocdée-Leroy as Communications and Investor Relations Director. Ms. Hocdée-Leroy brings the company her international experience and her expertise in corporate communications, the financial markets and investor relations. After graduating from EM ...

A new milestone achieved with IFNalpha-Kinoid in the phase I/II study in Lupus patients

29-Sep-2010 - Neovacs has received DSMB authorization to proceed to the next dose level in its ongoing phase I//II trial in lupus. Administration of the second dose level in patients recruited in July was completed as expected. Having reviewed the data related to these patients on September 24, the Data and ...